Menopause, HRT, and Healthy Aging

Few areas of medicine have whiplashed as hard as hormone therapy for menopause. For years it was widely prescribed, then a landmark trial sent prescriptions plummeting, and the interpretation of that trial has since been substantially revised. The result is a topic where the honest position requires holding nuance rather than a slogan.

How the evidence shifted

The Women’s Health Initiative (WHI), published in JAMA in 2002, randomized 16,608 postmenopausal women with an intact uterus to estrogen plus progestin or placebo. The trial was stopped early — after a mean of 5.2 years — because the data and safety monitoring board judged that overall risks exceeded benefits. The estrogen-plus-progestin arm showed increased risks across several outcomes, alongside some reductions.

Outcome	Hazard ratio (95% CI)	Direction
Coronary heart disease	1.29 (1.02–1.63)	Increased risk
Stroke	1.41 (1.07–1.85)	Increased risk
Breast cancer	1.26 (1.00–1.59)	Increased risk
Pulmonary embolism	2.13 (1.39–3.25)	Increased risk
Colorectal cancer	0.63	Reduced risk
Hip fracture	0.66	Reduced risk

Crucially, that headline population skewed older and further from menopause onset. Later analyses argued the risk-benefit balance depends heavily on when therapy starts and which formulation is used.

The current, more careful reading is that hormone therapy’s risks and benefits are not one-size-fits-all. Timing, formulation, dose, and individual risk factors change the equation substantially.

This is the “timing hypothesis,” sometimes called the window of opportunity: starting therapy near menopause onset, in appropriate candidates, looks more favorable than starting it many years later.

What hormone therapy is, and isn’t, for

The 2022 hormone therapy position statement of The Menopause Society (formerly NAMS) frames it clearly: hormone therapy is the most effective treatment for vasomotor symptoms (hot flashes, night sweats) and for genitourinary syndrome of menopause, and it has dose-related benefits for bone density.

Where the benefit-risk profile is most favorable

For women younger than 60 or within 10 years of menopause onset, the statement judges the benefit-risk balance favorable for treating bothersome vasomotor symptoms and preventing bone loss. Initiating therapy later — past 60, or more than 10–20 years out — carries a less favorable profile because absolute risks of cardiovascular events, stroke, and dementia rise.

Where it is not indicated

• Cardiovascular disease. Hormone therapy is not recommended as a primary prevention strategy for heart disease.
• Cognition and dementia. The statement explicitly says hormone therapy is not recommended at any age to prevent or treat cognitive decline or dementia.
• General “anti-aging” use. This outruns the evidence; the case rests on symptoms and specific indications, not a blanket longevity promise.

An individualized decision

Because the balance shifts with age, time since menopause, formulation, and personal risk factors such as clotting and breast-cancer history, this is a decision for a careful conversation with a clinician, not a rule that applies to everyone. The same therapy can be a sound choice for one woman and a poor one for another.

The takeaway

Hormone therapy is neither the villain of the 2000s nor a universal fountain of youth. The honest bottom line is that it is an effective, evidence-based treatment for menopausal symptoms with a risk-benefit profile that depends heavily on timing, formulation, and the individual. For longevity specifically — preventing heart disease or dementia — it is explicitly not recommended, and it should be approached as a personalized medical decision rather than a wellness default.

Sources

• Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women (WHI, JAMA 2002)
• Women’s Health Initiative — American College of Cardiology trial summary
• The 2022 Hormone Therapy Position Statement of The North American Menopause Society — summary